Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital

Journal of Hospital Infection

Volumn 64, Issue 4, 2006, Pages 348-351

  Cook, P P ^a   Catrou, P ^a   Gooch, M ^b   Holbert, D ^c  

^a EAST CAROLINA UNIVERSITY   (United States)

^b PITT COUNTY MEMORIAL HOSPITAL   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antibiotic usage; Fluoroquinolones; Meticillin resistant Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN;

ADULT; ARTICLE; BACTERIUM ISOLATE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG USE; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; INFECTION RATE; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PREVALENCE; RISK FACTOR; RISK REDUCTION; STAPHYLOCOCCUS INFECTION; TEACHING HOSPITAL; TERTIARY HEALTH CARE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CROSS INFECTION; HOSPITALS, TEACHING; HUMANS; INCIDENCE; INFECTION CONTROL; METHICILLIN RESISTANCE; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33750515915     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2006.06.033     Document Type: Article

References (14)

1. Diekema D.J., BootsMiller B.J., Vaughn T.E., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 (2004) 78-85
2. Witte W. Antibiotic resistance in Gram positive bacteria: epidemiological aspects. J Antimicrob Chemother 44 (1999) 1-9
3. Graffunder E.M., and Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 49 (2002) 999-1005
4. Monnet D., and Frimodt-Moller N. Antimicrobial-drug use and methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 7 (2001) 1-3
5. Hill D.A., Herford T., and Parratt D. Antibiotic usage and methicillin-resistant Staphylococcus aureus and analysis of causality. J Antimicrob Chemother 42 (2002) 676-677
6. Crowcroft N.S., Ronveaux O., Monnet D.L., and Mertens R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 20 (1999) 31-36
7. Weber S.G., Gold H.S., Hooper D.C., Karchmer A.W., and Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 9 (2003) 1415-1422
8. Monnet D.L., MacKenzie F.M., Lopez-Lozano J.M., et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 10 (2004) 1432-1441
9. Hoiby N., Jarlov J.O., Kemp M., et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 349 (1997) 167-169
10. Bisognano C., Vaudaux P., Rohner P., et al. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 44 (2000) 1428-1437
11. Li D., Renzoni A., Estoppey T., et al. Induction of fibronectin adhesins in quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin or by sigma B transcription factor activity is mediated by two separate pathways. Antimicrob Agents Chemother 49 (2005) 916-924
12. Jacoby G.A. Mechanisms of resistance to quinolones. Clin Infect Dis 41 (2005) S120-S126
13. Acar J.F., and Goldstein F.W. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24 Suppl. 1 (1997) S67-S73
14. Aubert G., Carricajo A., Vautrin A.-C., et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 59 (2005) 83-89